Tyra Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Tyra Biosciences, Inc. (TYRA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $16.54 per share as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $16.54.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $13.09.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $12.58.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $12.23.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $16.54 10-Q · filed 2026-08-04 |
| 2026-03-31 | $13.09 10-Q · filed 2026-05-13 |
| 2025-12-31 | $12.58 10-K · filed 2026-03-02 |
| 2025-09-30 | $12.23 10-Q · filed 2025-11-05 |
| 2025-06-30 | $13.34 10-Q · filed 2025-08-14 |
| 2025-03-31 | $13.46 10-Q · filed 2025-05-08 |
| 2024-12-31 | $13.43 10-K · filed 2025-03-27 |
| 2024-09-30 | $13.23 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.97 10-Q · filed 2024-08-07 |
| 2024-03-31 | $10.36 10-Q · filed 2024-05-09 |
| 2023-12-31 | $10.07 10-K · filed 2024-03-19 |
| 2023-09-30 | $10.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $8.42 10-Q · filed 2023-08-10 |
| 2023-03-31 | $7.94 10-Q · filed 2023-05-04 |
| 2022-12-31 | $7.91 10-K · filed 2023-03-22 |
| 2022-09-30 | $7.95 10-Q · filed 2022-11-03 |
| 2022-06-30 | $8.79 10-Q · filed 2022-08-04 |
| 2022-03-31 | $8.95 10-Q · filed 2022-05-05 |
| 2021-12-31 | $9.18 10-K · filed 2022-03-03 |
| 2021-09-30 | $2.89 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |